Moreover, by impairing P2Y14 activation, this approach could also limit the systemic supply of new inflammatory cells and contribute to alleviating the respiratory compromise observed in COVID-19 and preventing the exacerbation of the bradykinin storm, one of the main drivers of severe pulmonary complications [62]. This evidence concerns the gene P2RY14 and COVID-19.